Clinical trials: Head and Neck Cancers- Squamous Cell
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma of Esophagus
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer.
- Trial name
- AP (NCT04196075)
- Testing
- Andrographis Paniculata
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment…
- Trial name
- NCT06654297
- Testing
- Camrelizumab, Palbociclib(100mg), Palbociclib(125mg)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Squamous Cell Carcinoma of the Head and Neck
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient.
- Trial name
- COMMENCE (NCT02054442)
- Testing
- Cetuximab, Methotrexate
- Where
- 8 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Radboud University Medical Center
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck…
- Trial name
- NCT05366166
- Testing
- Pembrolizumab, Olaparib, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
Develop and Test the 'Multi-Faced Continuous Exercise Program' in Operable Head and Neck Cancer Patients
Background: Due to the disease location and related treatments in head and neck areas following with concurrent chemoradiation therapy (CCRT), patients might suffer a series of acute distress and limit their physical activities.
- Trial name
- NCT05267353
- Testing
- Exercise intervention program
- Volunteers
- 390 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Neoplasms
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell…
- Trial name
- NCT00402545
- Testing
- Cetuximab, Docetaxel, Cisplatin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
PARP Inhibitor for Esophageal Squamous Cell Carcinoma
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
This study is a prospective, multi-cohort, single-centre, phase II clinical trial designed to initially explore the efficacy and safety of sequential fluzoparib with chemoradiotherapy in pan-solid tumours.
- Trial name
- NCT06055166
- Testing
- Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
- Volunteers
- 120 people
- Sponsor
- Chongqing University Cancer Hospital
Head and Neck Cancer
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or…
- Trial name
- NCT00281866
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States, Spain
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oral Potentially Malignant Disorders, Oral Cavity Squamous Cell Carcinoma
Artificial Intelligence for the Diagnosis of Oral Lesions
Squamous cell carcinomas of the upper aerodigestive tract are among the most common cancers worldwide, with the oral cavity being the most frequent site.
- Trial name
- AID-OraL (NCT07529769)
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
This phase I/II trial investigates the best dose and effect of alisertib in combination with pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer. Alisertib may help block the growth of cancer..
- Trial name
- NCT04555837
- Testing
- Alisertib, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in HNSCC With Residual Disease After Radiation
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy).
- Trial name
- NCT02892201
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
- Trial name
- NCT06919666
- Testing
- NT219
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer
Objective: The aim of this study is to characterize the inflammatory response in patients with head and neck cancer. More specifically, the study intend to investigate inflammatory and genetic differences between the primary…
- Trial name
- NCT07131566
- Testing
- Sentinel Node detection and Biopsy
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Lars Olaf Cardell
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Squamous Cell Carcinoma, Head And Neck
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Given that up-regulation of the Wnt pathway has been identified as having a significant role in carcinogenesis in advanced head and neck squamous cell carcinoma, the investigator believes that inhibition of Porcupine via WNT974…
- Trial name
- NCT02649530
- Testing
- WNT974
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.